Antiproteinuric Effect of an N-Type Calcium Channel Blocker, Cilnidipine
- 1 January 2005
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Clinical and Experimental Hypertension
- Vol. 27 (8), 583-591
- https://doi.org/10.1080/10641960500298558
Abstract
The objective of the present study was to determine antiproteinuric effect of an N-type calcium channel blocker—cilnidipine. Subjects were 43 essential or renal hypertensive subjects who had been taking calcium channel blockers other than cilnidipine for at least 6 months. All patients had proteinuria greater than 0.2 g/day in spite of fair blood pressure control (< 150/90 mmHg). Calcium channel blockers in 25 patients (62 ± 3 years) were switched to cilnidipine (cilnidipine group), whereas other 18 patients (58 ± 3 years) continued to take originally prescribed calcium channel blockers (control group). The 24-hr urine collections were done at baseline and after 6 months of the follow-up period. Baseline characteristics including age, blood pressure levels, body mass index and creatinine clearance were similar between cilnidipine and control groups. Urinary protein excretion also was comparable between cilnidipine (0.61 ± 0.10 g/day) and control (0.86 ± 0.17 g/day) groups. Urinary protein significantly decreased after 6 months in cilnidipine group (− 0.21 ± 0.11 g/day, − 36%, p < 0.01), whereas it did not change in control group (+ 0.01 ± 0.15 g/day, 0.4%, ns). There were no significant changes in blood pressure, serum creatinine, creatinine clearance, estimated protein intake, and urinary salt excretion during the follow-up period in either group. The reduction of urinary protein by cilnidipine was evident in essential hypertensives (− 54 ± 9%, n = 18, p < 0.01) but not in renal hypertensives (+ 10 ± 35%, n = 7, ns). Results suggest that cilnidipine has an antiproteinuric effect especially in patients with essential hypertension.Keywords
This publication has 28 references indexed in Scilit:
- Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension-a Report of the Japanese Losartan Therapy Intended for the Global Renal Protection Hypertensive Patients (JLIGHT) StudyHypertension Research, 2004
- Follow-up of renal function in treated and untreated older patients with isolated systolic hypertensionJournal of Hypertension, 2001
- The hyperfiltration theory: A paradigm shift in nephrologyKidney International, 1996
- Disparate Effects of Calcium Antagonists on Renal Microcirculation.Hypertension Research, 1996
- Inhibitory Effect of Cilnidipine on Vascular Sympathetic Neurotransmission and Subsequent Vasoconstriction in Spontaneously Hypertensive RatsThe Japanese Journal of Pharmacology, 1995
- Long-term comparison between captopril and nifedipine in the progression of renal insufficiencyKidney International, 1992
- Effects of a New Dihydropyridine Derivative, FRC-8653, on Blood Pressure in Conscious Spontaneously Hypertensive Rats.Journal of Pharmacobio-Dynamics, 1992
- Progression of renal insufficiency: Role of blood pressureKidney International, 1989
- Simple portable device for sampling a whole day's urine and its application to hypertensive outpatients.Hypertension, 1983
- Incidence of Radiographically Evident Bone Disease, Nephrocalcinosis, and Nephrolithiasis in Various Types of Renal Tubular AcidosisNew England Journal of Medicine, 1982